¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"test type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • disc sensitivity test
    ¿ø¹Ý¹Î°¨°Ë»ç
  • discrimination test
    ½Äº°°Ë»ç, ÆÇº°°Ë»ç
  • dot blot test
    Á¡Àû°Ë»ç, ¾ó·èÁ¡°Ë»ç
  • exercise stress test
    ¿îµ¿Àڱذ˻ç
  • exercise tolerance test
    ¿îµ¿³»¼º°Ë»ç
  • estrogen challenge test
    ¿¡½ºÆ®·Î°ÕºÎÇϰ˻ç
  • fermentation test
    ¹ßÈ¿°Ë»ç
  • fern test
    ¾çÄ¡Çü¼º°Ë»ç
  • field test
    ½ÇÁõ°Ë»ç
  • finger-nose test
    ¼Õ°¡¶ôÄÚ°Ë»ç
  • finger-to-finger test
    ¼Õ°¡¶ô¸Â´ë±â°Ë»ç
  • fistula test
    »û±æ°Ë»ç, ´©°ø°Ë»ç
  • flocculation test
    ¼ØÅÐħÀü°Ë»ç
  • fluctuation test
    µé³¯Âߺ¯À̰˻ç
  • fluorescent antibody test
    Çü±¤Ç×ü°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • challenge test
    À¯¹ß°Ë»ç
  • chelation test
    ų·¹ÀÌÆ®È­°Ë»ç
  • chemiluminescence test
    È­Çй߱¤°Ë»ç
  • chemstrip test
    È­Çжì°Ë»ç
  • chi-square test
    Ä«ÀÌÁ¦°ö°ËÁ¤
  • children apperception test
    ¾Æµ¿Åë°¢°Ë»ç
  • clearance test
    û¼ÒÀ²½ÃÇè
  • clock-drawing test
    ½Ã°è±×¸®±â°Ë»ç
  • closed cup flash test
    ¹ÐÆó½ÄÀÎÈ­Á¡°Ë»ç
  • clot retraction test
    Ç÷º´ÅðÃà°Ë»ç, Çǵ¢À̵ڴç±è°Ë»ç
  • coagulase test
    Ç÷ÀåÀÀ°íÈ¿¼Ò°Ë»ç
  • cold pressure test
    Çѳþйڰ˻ç
  • colony inhibition test
    ¼¼Æ÷±ºÇü¼º¾ïÁ¦°Ë»ç, Áý¶ôÇü¼º¾ïÁ¦°Ë»ç
  • color form sorting test
    »öäÇüÅÂÃ߸®±â°Ë»ç
  • colorimetric caries susceptibility test
    ¿ì½Ä°¨¼ö¼ººñ»ö½ÃÇè
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • DNase test
    DNA ºÐÇØÈ¿¼Ò½ÃÇè
  • DST=dexamethasone supression test
    µ¦»ç¸ÞŸ¼Õ ¾ïÁ¦°Ë»ç
  • Dehydration test
    Å»¼ö°Ë»ç
  • Denver Developmental Screening Test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç(Û¡Ó¹ðàÞÛËþÞÛ)
  • Denver developmental screening test
    µ§¹ö¹ßÀ°¼±º°¹ý.
  • Dick test
    µñÅ©½ÃÇè
  • Dick test
    µñ °Ë»ç
  • Donath-Landsteiner test
    µµ³ª¾²¶õÆ®½ºÅ¸ÀÌ³Ê °Ë»ç
  • Draw-A-Person test(DAP)
    Àι°È­°Ë»ç
  • Du test
    Du °Ë»ç (ÁÖÀÇ : u ´Â À­Ã·ÀÚÀÓ)
  • Eleks gel-precipitin test
    ¿¤·ºÅ©ÇÑõÆòÆÇħ°­¹ý (µðÇÁÅ׸®¾Æµ¶¼Ò µ¿Á¤¹ý)
  • Falcon assay screening test
    ÆÈÄܺм®¼±º°½ÃÇè
  • Farnworth D-15 test
    ÆÄ¸¥¿ö½º15»ö»ó°Ë»ç
  • Farnworth-Munsell 100 hue test
    ÆÄ¸¥¿ö½º-¹®¼¿ 100»ö»ó°Ë»ç
  • Freda test
    ÇÁ·¹´Ù½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • lymphatic type
    ¸²ÇÁÇü(¡­úþ).
  • mating type
    ±³¹èÇü
  • men type
    MEN Çü(¡­ û¡)
  • meningeal type
    ¼ö¸·Çü(âÐØ¯úþ).
  • metaphyseal dysostosis dominant type
    °ñ °£´Ü¼º À̰ñÁõ ¿ì¼ºÇü(ÍéÊÏÓ®àõì¶ÍéñøéÐàõúþ).
  • metaplastic bone (type)
    È­»ý°ñ(Çü)(ûùßæÍéû¡).
  • mixed type of artery
    È¥ÇÕÇüµ¿¸Æ
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü(¡­û¡).
  • monocytic type
    ´ÜÇÙ±¸Çü(Ó¤ú·Ï¹û¡)
  • monocytic type
    ´ÜÇÙ±¸Çü(?Ì´).
  • muscular type of artery
    ±ÙÀ°Çüµ¿¸Æ
  • muscular type of lymphatic vessel
    ±ÙÀ°Çü¸²ÇÁ°ü
  • muscular type of vein
    ±ÙÀ°ÇüÁ¤¸Æ
  • mutation, plaque-type
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • zinc sulfate turbidity test
    Ȳ»ê¾Æ¿¬(üÜ߫䬿ç) ȥʵµ½ÃÇè(ûèöúÓøãËúÐ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
ATD Alzheimer-type dementia; androstatrienedione; anthropomorphic test dummy; antithyroid drug; aqueous ...
BlT bleeding time; blood test; blood type, blood typing
TS Takayasu syndrome; Tay-Sachs; temperature sensitivity; temperature, skin; temporal stem; tensile str...
AGT Anti-Globulin Test
  = Coombs' Test
ASTZ test Anti-Strepto-Zyme Test
  = ASZT
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
C-T Conditioning-Test
CPT Continuous Performance Test
CST contraction stress test
DAT DIRECT AGGLUTINATION TEST
DMT Defence Mechanism Test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • automated reagin test
    ÀÚµ¿È­ ¸®¾ÆÁø ½ÃÇè
  • Ayer's test
    ¿¡ÀÌ¾î ½ÃÇè
  • Babinski-Weil test
    ¹Ùºó½ºÅ°-¿ÍÀÏ ½ÃÇè
  • Bacitracin differential disk test
    ¹Ù½ÃÆ®¶ó½Å °¨º°ÆÇ ½ÃÇè, ¹Ù½ÃÆ®¶ó½Å °¨º° ¿øÆÇ ½ÃÇè
  • bacteriolytic test
    ¿ë±Õ ½ÃÇè
  • bacteriophage neutralization test
    ¹ÚÅ׸®¿À ÆÄ¾ÆÁö ÁßÈ­ ½ÃÇè
  • Baermann test
    º£¾î¸¸ ½ÃÇè
  • bar-reading test
    ¹Ù-¸®µù ½ÃÇè
    ¾ç¾È½Ã¿Í ÀÔü ½Ã¿¡ ´ëÇÑ ½ÃÇèÀ¸·Î¼­, ¾çÂÊ ´«°ú ÀμâµÈ ÆäÀÌÁö¿Í »çÀÌ Áß°£Âë¿¡ ÀÚ¸¦ ³õ´Â´Ù. À̰ÍÀº ¶ÇÇÑ ÀÔü½ÃÀÇ ÈÆ·Ã¿¡µµ ÀÌ¿ëµÈ´Ù.
  • barany's test
    ¹Ù´Ï´Ï ¿Âµµ ½ÃÇè
  • Bardach's test
    ¹Ù¸£´ÙÇÏ ´Ü¹éÁú °ËÃâ¹ý
  • Bareggi's test
    ¹Ù·º±â ½ÇÇè
    ƼǪ½º ȯÀÚ¿¡¼­´Â äÇ÷ ÈÄÀÇ Ç÷º´ ¼öÃàÀÌ ºÒ·®ÇÏ´Ù.
  • Barfood's test
    ¹Ù¸£Ç£µå ½ÇÇè
    ȯ¿ø´çÀÇ °ËÃâ ½ÇÇè.
  • Barral's test
    ¹Ù¶ö ½ÃÇè
    20% ¿À¸£ÅäÆä³î¼³Æù»êÀ¸·Î ¿ä¸¦ ÁßÃþÇÒ ¶§ ¹é»ö ·ûÀÌ ³ªÅ¸³ª¸é ´Ü¹é, ³ì»ö·ûÀÌ ³ªÅ¸³ª¸é ´ãÁó »ö¼Ò°¡ ÀÖÀ½À» ³ªÅ¸³½´Ù.
  • Becker's test
    º£Ä¿ ½ÃÇè
  • Bekhterev's test
    º£Å©Å×·¹ºê ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
deoxyribonucleases, type III site-specific <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity.
The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.5
(12 Dec 1998)
deoxyribonucleases, type II site-specific <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.4
(12 Dec 1998)
deoxyribonucleases, type I site-specific <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.3
(12 Dec 1998)
diabetes, type 1 Insulin dependent diabetes or juvenile diabetes.
(12 Dec 1998)
diabetes, type 2 Non-insulin dependent diabetes, adult-onset diabetes or insulin-resistant diabetes.
(12 Dec 1998)
disease, gaucher's type 1 A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States.
(12 Dec 1998)
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
influenza type a A common acute viral infection of the nasopharynx and respiratory tract which occurs in epidemic forms. A common cause is the Influenza a virus. Annual vaccination is recommended for those in high risk groups (health care workers, elderly and immunocompromised) for influenza infection.
Common symptoms include runny nose, fever, weakness, headache, body aches, muscle aches, nausea and back pain. Treatment of symptoms has been successful with amantadine or rimantadine.
(27 Sep 1997)
interferon type I <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon type II <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
ocean-type fish An anadromous fish that shows no indication on its scales or other hard parts of an extended freshwater residence early in its life.
(09 Oct 1997)
Ellis type 1 glomerulonephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 1 nephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 2 glomerulonephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
Ellis type 2 nephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á